Trulicity (Dulaglutide) in Children Under 12: School and Activity Considerations

Is Dulaglutide Approved for Children Under 12?

Dulaglutide carries FDA approval for type 2 diabetes management in patients aged 10 years and older, based on the AWARD-PEDS trial. Children younger than 10 fall entirely outside the approved indication. This boundary matters because any prescription for a child aged 9 or below is off-label use, which shifts documentation and informed-consent obligations to the prescribing clinician.

What AWARD-PEDS Actually Found

The AWARD-PEDS randomized controlled trial enrolled 154 pediatric patients aged 10 to 17 with type 2 diabetes. At 26 weeks, dulaglutide 0.75 mg reduced HbA1c by a mean of 0.6 percentage points vs. Placebo, and the 1.5 mg dose reduced it by 0.9 percentage points (P<0.001 for both doses vs. Placebo). [1] Body weight did not differ significantly from placebo in this cohort, which contrasts with adult GLP-1 data and is relevant when framing expectations for families.

The ADA's 2024 Standards of Medical Care in Diabetes state that GLP-1 receptor agonists "may be used as adjunct to metformin in youth with type 2 diabetes when additional glucose lowering is needed." [2] That framing applies from age 10 upward.

Children Aged 10 to 11: The Practical Reality

A child who just turned 10 and starts dulaglutide will likely spend most of the school week unaffected by the medication, since the injection is given once weekly. The school-day intersection with the drug is mainly logistical: where is the pen stored, who knows about it, and what happens if nausea strikes at lunch. [3]

Injection Logistics at School

Most families give the weekly dulaglutide injection at home, in the evening or morning, on a fixed day of the week. That schedule means the school nurse will rarely, if ever, need to administer the dose. The school does still need documentation.

What the School Health File Must Contain

The American Diabetes Association recommends a written Diabetes Medical Management Plan (DMMP) for every child with diabetes attending school. [4] For a child on dulaglutide, that plan should specify:

• The drug name, dose (0.75 mg or 1.5 mg), and injection day
• Whether the child self-injects or requires adult administration
• Storage instructions for any backup pen kept on campus
• Recognition and response steps for hypoglycemia, even though risk is low with dulaglutide monotherapy
• Contact information for the prescribing endocrinologist

Section 504 of the Rehabilitation Act requires schools to provide reasonable accommodations for students managing chronic conditions including diabetes. [5] A DMMP is the standard vehicle for invoking those accommodations.

Storing a Backup Pen at School

Trulicity single-dose pens must be refrigerated at 36 to 46°F (2 to 8°C) before first use. Once removed from the refrigerator, a pen may be stored at room temperature up to 77°F (25°C) for up to 14 days. [6] A school health office refrigerator is the correct location for any backup pen. The pen should be kept in its original carton to protect it from light, and the expiration date should be checked at least monthly by the school nurse.

Self-Injection Readiness in Young Children

Children aged 10 to 11 vary considerably in their readiness to self-inject. The Trulicity autoinjector pen was designed to simplify the process: the needle is hidden, injection is single-step, and no manual dialing is required. A 2022 survey published in Pediatric Diabetes found that children as young as 10 could perform the injection sequence correctly after one training session when a caregiver was present. [7] Still, the school nurse should be trained to assist or supervise injection if needed, and that role should be documented in the DMMP.

Hypoglycemia Risk and Recognition

Dulaglutide works through glucose-dependent insulin secretion. Because insulin release increases only when blood glucose is elevated, the medication carries a low intrinsic risk for hypoglycemia when used as monotherapy. [8] This differs substantially from insulin and sulfonylureas, which teachers and coaches may be more familiar with.

When Risk Is Not Low

Hypoglycemia risk rises when dulaglutide is combined with insulin or a sulfonylurea such as glimepiride. [9] If a child's regimen includes any of these agents, the school must treat their risk profile as equivalent to an insulin-using child. The DMMP should specify the combination explicitly and include glucose targets, symptom recognition training for staff, and glucagon access.

The Endocrine Society's clinical practice guideline on hypoglycemia in non-critically ill patients recommends a threshold of 70 mg/dL (3.9 mmol/L) as the standard alert value. [10] For a school setting, any reading below 70 mg/dL should prompt the response protocol regardless of symptoms.

Training Classroom Teachers

Teachers are the first adult most children will see during a hypoglycemic episode. A brief annual training session, typically 20 to 30 minutes, covering symptom recognition (shakiness, pallor, confusion, irritability) and the 15-15 rule (15 grams of fast-acting carbohydrate, recheck in 15 minutes) is standard practice in pediatric diabetes care. [11] The CDC's diabetes-at-school resources provide free printable guidance aligned with this protocol. [12]

Physical Activity and Glucose Response

Exercise changes glucose dynamics in ways that interact with GLP-1 receptor agonist therapy. Children at school engage in a mix of aerobic activity (distance running, sustained play), anaerobic bursts (sprinting, competitive sports), and resistance activity (gym class, climbing). Each type carries a different glucose trajectory.

Aerobic Activity

Sustained aerobic exercise increases glucose uptake by skeletal muscle through insulin-independent pathways, which can lower blood glucose during and for up to 24 hours after activity. [13] For a child on dulaglutide monotherapy, this effect is usually safe because the drug will not drive additional insulin secretion into a low-glucose environment. For a child on a combination regimen, a pre-activity glucose check is advisable before any sustained activity lasting more than 20 minutes.

Anaerobic and High-Intensity Activity

Short-burst, high-intensity activity activates counterregulatory hormones (catecholamines, glucagon) that can transiently raise blood glucose above baseline. [14] This means a child may see glucose rise during competitive sprinting or interval drills even while on a glucose-lowering drug. Families should know this is expected, not a sign of medication failure.

Practical School PE Protocol

The following three-tier protocol can be shared with school nurses and PE teachers for children aged 10 to 11 on dulaglutide:

• Green (glucose above 126 mg/dL): Full participation in all activities.
• Yellow (glucose 70 to 126 mg/dL): Participate; have 15 grams of fast-acting carbohydrate accessible on the sideline.
• Red (glucose below 70 mg/dL): Treat hypoglycemia first, recheck, do not return to activity until glucose is above 100 mg/dL for at least 15 minutes.

This framework aligns with the International Society for Pediatric and Adolescent Diabetes (ISPAD) 2022 exercise guidelines, which recommend a pre-exercise glucose target of 90 to 180 mg/dL for children with diabetes. [15]

After-School Sports and Extracurricular Activity

Dulaglutide's half-life is approximately 5 days, meaning drug levels are essentially steady throughout the week after the first 4 to 5 weeks of therapy. [6] A child's Tuesday afternoon soccer practice carries the same pharmacological context as their Thursday swim meet. Families and coaches do not need to adjust activity plans based on injection day, as long as glucose monitoring is consistent.

After-school coaches should receive a one-page summary of the child's plan. A study in Diabetes Care found that peer and coach awareness of a child's diabetes management plan was associated with fewer missed activity sessions and higher caregiver confidence scores. [16]

Managing GI Side Effects During the School Day

Nausea is the most reported adverse effect of dulaglutide in the AWARD-PEDS trial, affecting approximately 17% of participants on the 1.5 mg dose. [1] Vomiting occurred in roughly 10%. These rates are highest during the first 4 weeks after each dose step.

Timing the Injection to Minimize School-Day Nausea

The injection does not need to be given on any specific day of the week, but timing it strategically can reduce interference with school attendance. Giving the injection on a Friday evening means peak GI symptoms fall during the weekend, when the child is at home. [17] This approach requires some flexibility in scheduling but is a reasonable adjustment endorsed by pediatric endocrinology practice guidelines.

What to Tell the School Nurse

If nausea does occur at school, the school nurse should know:

• Dulaglutide-associated nausea is usually mild to moderate and self-limited.
• Oral hydration and small, bland food servings (crackers, rice) are appropriate supportive measures.
• Vomiting that prevents adequate oral intake for more than 4 hours warrants a call to the prescribing physician, especially if the child is on insulin concurrently.
• Anti-emetics are not routinely prescribed alongside dulaglutide in pediatric patients without physician direction. [18]

A 2021 systematic review in JAMA Pediatrics found that GI adverse events with GLP-1 receptor agonists in youth were "transient and manageable with dietary modification," typically resolving within 4 to 8 weeks of starting or uptitrating the drug. [19]

School Lunch Considerations

Dulaglutide slows gastric emptying. Smaller, more frequent meals are better tolerated than large cafeteria-style portions, particularly in the first month of therapy. [20] Families should notify the school nutrition coordinator if the child requires modified portion access or a mid-morning snack. Under Section 504, a medically documented need for dietary accommodation must be addressed by the school. [5]

Communicating With the School Team

A clear communication chain prevents confusion and delays when a school-day issue arises. The core team includes the prescribing endocrinologist or primary care physician, the school nurse, the classroom teacher (for hypoglycemia recognition), and, where applicable, the PE teacher or coach.

The Annual School Meeting

Many pediatric diabetes programs recommend an annual back-to-school meeting, either in person or by teleconference, before the first day of class. [4] This meeting should cover:

• Current medication list and any changes from the prior year
• Glucose targets and monitoring schedule during school hours
• Emergency contacts and after-hours endocrine coverage phone numbers
• A review of the DMMP with all parties signing to confirm receipt

The National Diabetes Education Program (NDEP), a joint initiative of the NIH and CDC, provides a standardized "Helping the Student with Diabetes Succeed" toolkit that many schools already use as a template for these meetings. [21]

Documentation for Field Trips and School Events

Field trips create logistical gaps: the school nurse may not attend, there may be limited access to refrigeration, and the activity level is unpredictable. For a child on dulaglutide, field-trip planning should confirm:

• Who is carrying the backup pen and emergency glucose supplies
• Whether the chaperone has received hypoglycemia recognition training
• The contact number for the prescribing physician

Because dulaglutide is a once-weekly drug, the chance that a field trip coincides exactly with injection day is roughly one in seven. If it does, the injection should be given at home the morning of the trip, not administered during the trip itself.

Transition Planning as the Child Approaches Age 12

Children move through the <12 age bracket quickly. A child who starts dulaglutide at age 10 will be in a different developmental and physiological category by age 12 to 13, with changing body composition, increasing insulin resistance during mid-puberty, and shifting activity patterns.

Puberty and Insulin Resistance

Puberty is associated with a 30% reduction in insulin sensitivity compared to pre-pubertal and post-pubertal states, driven primarily by growth hormone and IGF-1 surges. [22] This means a child who achieves adequate glycemic control at age 10 on dulaglutide 0.75 mg may need dose uptitration or add-on therapy by age 12 to 13. The prescribing team should anticipate this and build dose-review checkpoints into the long-term plan.

Shifting to Adolescent Self-Management

By age 12 to 13, most guidelines recommend moving toward supervised self-management, where the child performs their own injection under caregiver observation before transitioning to fully independent administration. [23] The school DMMP should be updated to reflect each change in independence level, and the school nurse role may shift from administering the injection to simply logging that it was completed.

A 2023 cohort study in Pediatric Diabetes (N=89 youth aged 10 to 16 with type 2 diabetes) found that adolescents who received structured diabetes self-management education showed a 0.7 percentage-point greater HbA1c reduction at 12 months compared to those receiving standard care alone. [24] Incorporating the school environment into that education structure strengthens outcomes.